Related references
Note: Only part of the references are listed.The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases
Tamer Abou Youssif et al.
CANCER (2011)
Increased activated Akt expression in renal cell carcinomas and prognosis
Martina Hager et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C
Valeria Facchinetti et al.
EMBO JOURNAL (2008)
Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma
Lizhi He et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2007)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Targeting the PI3K-Akt pathway in kidney cancer
Jin-Young Park et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Activation of the mTOR signaling pathway in renal clear cell carcinoma
Victoria A. Robb et al.
JOURNAL OF UROLOGY (2007)
PTEN expression in renal cell carcinoma and oncocytoma and prognosis
Martina Hager et al.
PATHOLOGY (2007)
The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation
Ji-Hyun Chung et al.
HUMAN MOLECULAR GENETICS (2006)
Prognostic significance of activated AKT expression in soft-tissue sarcoma
Yasuhiko Tomita et al.
CLINICAL CANCER RESEARCH (2006)
Molecularly targeted therapy in renal cell carcinoma
W. Kimryn Rathmell et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Akt activation correlates with adverse outcome in tongue cancer
E Massarelli et al.
CANCER (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Stability of phosphoprotein as a biological marker of tumor signaling
AF Baker et al.
CLINICAL CANCER RESEARCH (2005)
High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB
T Van de Sande et al.
JOURNAL OF PATHOLOGY (2005)
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
S Hara et al.
ANNALS OF ONCOLOGY (2005)
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein
JH Chung et al.
CANCER RESEARCH (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma
S Yamamoto et al.
CLINICAL CANCER RESEARCH (2004)
PI 3-kinase, Akt and cell survival
J Downward
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway
LA deGraffenried et al.
ANNALS OF ONCOLOGY (2004)
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome
AR Panigrahi et al.
JOURNAL OF PATHOLOGY (2004)
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer
JI Kreisberg et al.
CANCER RESEARCH (2004)
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage
O David et al.
CLINICAL CANCER RESEARCH (2004)
Staging Laparoscopy in gastric cancer: A single port method
JH Lee et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
A decade of tyrosine kinases: from gene discovery to therapeutics
RJ Craven et al.
SURGICAL ONCOLOGY-OXFORD (2003)
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling
BD Manning et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2003)
Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma
A Horiguchi et al.
JOURNAL OF UROLOGY (2003)
Akt kinases in breast cancer and the results of adjuvant therapy
O Stal et al.
BREAST CANCER RESEARCH (2003)
Rheb fills a GAP between TSC and TOR
BD Manning et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
Loss of tumor suppressor protein PTEN during renal carcinogenesis
W Brenner et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma
DC Whiteman et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
The protein kinase B/Akt signalling pathway in human malignancy
KM Nicholson et al.
CELLULAR SIGNALLING (2002)
The AKT kinase is activated in multiple myeloma tumor cells
JH Hsu et al.
BLOOD (2001)
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas
K Kurose et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
XP Zhou et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells
A Perren et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors
O Gimm et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
